Through real-time PCR, we have shown that ADAM17 was the key player in mediating EGFR activation, by the demonstration that ADAM17 inhibitor TAPI-1 treatment significantly suppressed the infection-induced transactivation of EGFR by preventing the proteolysis and secretion of HB-EGF. This evidence concerns the gene ADAM17 and infection.